We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Trumps Blood For Zika Testing

By LabMedica International staff writers
Posted on 08 Jun 2016
Limited data suggest Zika virus is excreted in multiple body fluids, including urine and saliva and that urine and saliva might be more appropriate specimens than blood samples for evaluating Zika virus disease.

The interim diagnostic testing guidance for the Zika virus recommends real-time reverse transcription-polymerase chain reaction (rRT-PCR) testing for urine specimens obtained two weeks after the illness starts. More...
The Zika virus ribonucleic acid (RNA) is almost undetectable in blood samples after the first week of illness.

Scientists from the Centers for Disease Control and Prevention (CDC, Atlanta GA, USA) and their colleagues collected multiple specimen types from persons with suspected Zika virus disease. Urine specimens were collected from 70 patients with suspected Zika virus disease from zero to 20 days after symptom onset. In 66 cases, persons had urine and serum specimens collected on the same day. The majority of these persons were female (64%), white (77%), and Hispanic (71%), with a median age of 46 years, age range 23 to76 years.

Zika virus rRT-PCR was performed at the Bureau of Public Health Laboratories (BPHL, Tampa, FL, USA) using a laboratory-developed test based on a previously published protocol using two RT-PCR targets. The teams found urine samples were the best at flagging Zika, with 93% of specimens collected within 20 days of symptoms first appearing showing positive results. Urine specimens also displayed positive results 82% of the time when samples were collected more than five days after symptoms cropped up. Urine samples were positive 95% of the time when the specimens were obtained the same day or within five days of illness onset as compared to 56% for blood samples.

The authors concluded that the results of testing conducted suggest that urine might be the preferred specimen type to identify acute Zika virus disease. Rates of detection from urine were higher than from serum, even during the first few days after symptom onset and continuing after day five, when no serum specimens tested in this evaluation had detectable RNA. Among pregnant women, this ability to confirm Zika virus is important because close monitoring during pregnancy is recommended for women with confirmed Zika virus disease.

The ease of collection of urine specimens is an additional advantage. This report also demonstrated that saliva specimens (another specimen that is easily obtained) can also yield a higher rate of RNA detection than serum even during the first five days; the detection rate in saliva also approaches the detection rate in urine. However, no cases were identified through saliva testing alone. The study was published on May 13, 2016, in the journal Morbidity and Mortality Report.

Related Links:
Centers for Disease Control and Prevention
Bureau of Public Health Laboratories


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Hematology Analyzer
Medonic M32B
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new test is redefining access to early endometrial cancer detection (Photo courtesy of Shutterstock)

Non-Invasive Liquid-Based Cytology Test Enables Early Endometrial Cancer Detection

Endometrial cancer is the fourth most common cancer among women in the United States, with over 69,000 new cases expected in 2025. Yet many diagnoses occur late, particularly in women who face inconclusive... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.